Empagliflozin Improves Liver Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial - Concepedia

Concepedia

Publication | Open Access

Empagliflozin Improves Liver Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

DOI Full Paper Access

165

Citations

59

References

2021

Year

Haleh Chehrehgosha, Masoudreza Sohrabi, Faramarz Ismail‐Beigi, Mojtaba Malek, Mohammad Reza Babaei, Farhad Zamani, Hossein Ajdarkosh, Mahmoodreza Khoonsari, Afshin Eshghi Fallah, Mohammad E. Khamseh

Diabetes Therapy

References

	Year	Citations

Page 1